Evidence map›Paper›PMID 39575884›Full record

ArticleDevelopment (Cambridge, England)2024

Phospho-regulation of ASCL1-mediated chromatin opening during cellular reprogramming.

Roberta Azzarelli, Sarah Gillen, Frances Connor, Jethro Lundie-Brown, Francesca Puletti, Rosalind Drummond, Ana Raffaelli, Anna Philpott

Abstract read
In one paragraph

Article in Development (Cambridge, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Roberta AzzarelliCambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge CB2 0AW, UK.ORCID 0000-0002-8160-7538
Sarah GillenCambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge CB2 0AW, UK.
Frances ConnorCambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge CB2 0AW, UK.ORCID 0000-0003-2858-9411
Jethro Lundie-BrownCambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge CB2 0AW, UK.ORCID 0000-0003-3403-1094
Francesca PulettiCambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge CB2 0AW, UK.
Rosalind DrummondCambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge CB2 0AW, UK.
Ana RaffaelliCambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge CB2 0AW, UK.
Anna PhilpottCambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge CB2 0AW, UK.ORCID 0000-0003-3789-2463

Funding

Cancer Research UK A25636Medical Research Council MC_PC_17230Royal Society RGS/R2/242202Royal Society RGS\R2\242202University College LondonWellcome - MRC Cambridge Stem Cell Institute, University of Cambridge 203151/A/16/ZWellcome - MRC Cambridge Stem Cell Institute, University of Cambridge 203151/Z/16/ZWellcome TrustWellcome Trust 203151/Z/16/ZWellcome Trust 212253/Z/18/Z
6 · The paper itself

Abstract

The proneural transcription factor ASCL1 regulates neurogenesis and drives somatic cell reprogramming into neurons. However, not all cell types can be reprogrammed by ASCL1, raising the questions of what provides competence and how we can overcome barriers to enable directed differentiation. Here, we investigate how levels of ASCL1 and its phosphorylation modulate its activity over progressive lineage restriction of mouse embryonic stem cells. We find that inhibition of ASCL1 phosphorylation enhances reprogramming of both mesodermal and neuroectodermal cells, while pluripotent cells remain refractory to ASCL1-directed neuronal differentiation. By performing RNA-seq and ATAC-seq in neuroectoderm, we find that un(der)phosphorylated ASCL1 causes increased chromatin accessibility at sites proximal to neuronal genes, accompanied by their increased expression. Combined analysis of protein stability and proneural function of phosphomutant and phosphomimetic ASCL1 reveals that protein stability plays only a marginal role in regulating activity, while changes in amino acid charge cannot fully explain enhanced activity of the serine-proline mutant variants of ASCL1. Our work provides new insights into proneural factor activity and regulation, and suggests ways to optimize reprogramming protocols in cancer and regenerative medicine.

Indexed as

Basic Helix-Loop-Helix ProteinsCellular ReprogrammingChromatinAnimalsCell DifferentiationMesodermMiceMouse Embryonic Stem CellsNeurogenesisNeuronsPhosphorylationProtein StabilityAscl1 protein, mouseBasic Helix-Loop-Helix ProteinsChromatinCell fate reprogrammingChromatin accessibilityEmbryonic stem cellsNeurogenesisPhosphorylationProneural transcription factors

Identifiers

PMID39575884
PMCPMC11664170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.